Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature

Current first-line systemic treatment in most patients with metastatic hormone receptor-positive, HER-2 negative breast cancer is an aromatase inhibitor in combination with a cyclin dependant kinase (CDK) 4/6 inhibitor. Frequently, these patients require palliative radiotherapy (RT) for symptomatic...

Full description

Bibliographic Details
Main Authors: Steven David, Gwo Ho, Daphne Day, Marion Harris, Jennifer Tan, Shom Goel, Gerard G. Hanna, Ranjana Srivastava, Gill Kruss, Lachlan McDowell, Michelle White
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Translational Oncology
Subjects:
CDK 4/6 inhibitor
Radiotherapy
Toxicity
Radiation recall
Palliative
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304319

Similar Items

Similar Items